The burden of illness in patients with moderate to severe chronic obstructive pulmonary disease in Canada

Por Maleki-Yazdi, M Reza, Kelly, Suzanne M, Lam, Sy S, Marin, Mihaela, Barbeau, Martin, Walker, Valery
Publicado em 2012

Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol

Por Singh, Dave, Maleki-Yazdi, M Reza, Tombs, Lee, Iqbal, Ahmar, Fahy, William A, Naya, Ian
Publicado no Int J Chron Obstruct Pulmon Dis (2016)

Assessing Short-term Deterioration in Maintenance-naïve Patients with COPD Receiving Umeclidinium/Vilanterol and Tiotropium: A Pooled Analysis of Three Randomized Trials

Por Maleki-Yazdi, M. Reza, Singh, Dave, Anzueto, Antonio, Tombs, Lee, Fahy, William A., Naya, Ian
Publicado no Adv Ther (2016)

New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology

Por D’Urzo, Anthony D, Cazzola, Mario, Hanania, Nicola A, Buhl, Roland, Maleki-Yazdi, M Reza
Publicado no Int J Chron Obstruct Pulmon Dis (2018)

Comprehensive assessment of the safety of olodaterol 5 µg in the Respimat(®) device for maintenance treatment of COPD: comparison with the long-acting β(2)-agonist formoterol

Por Koch, Andrea, Watz, Henrik, Maleki-Yazdi, M. Reza, Bothner, Ulrich, Tetzlaff, Kay, Voß, Florian, McGarvey, Lorcan
Publicado no NPJ Prim Care Respir Med (2017)

Randomized, Double-Blind, Dose-Finding Study for Tiotropium when Added to Olodaterol, Administered via the Respimat(®) Inhaler in Patients with Chronic Obstructive Pulmonary Diseas...

Por Aalbers, René, Maleki-Yazdi, M. Reza, Hamilton, Alan, Waitere-Wijker, Stella, Zhao, Yihua, Amatto, Valeria C., Schmidt, Olaf, Bjermer, Leif
Publicado no Adv Ther (2015)